345 related articles for article (PubMed ID: 33799862)
1. A Scoping Review on Lipocalin-2 and Its Role in Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma.
Krizanac M; Mass Sanchez PB; Weiskirchen R; Asimakopoulos A
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799862
[TBL] [Abstract][Full Text] [Related]
2. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
[TBL] [Abstract][Full Text] [Related]
3. Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?
Stefano JT; de Oliveira CP; Corrêa-Giannella ML; Soares IC; Kubrusly MS; Bellodi-Privato M; de Mello ES; de Lima VM; Carrilho FJ; Alves VA
Liver Int; 2011 Mar; 31(3):377-85. PubMed ID: 21108736
[TBL] [Abstract][Full Text] [Related]
4. The Natural Course of Non-Alcoholic Fatty Liver Disease.
Calzadilla Bertot L; Adams LA
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213358
[TBL] [Abstract][Full Text] [Related]
5. S100 Proteins in Fatty Liver Disease and Hepatocellular Carcinoma.
Delangre E; Oppliger E; Berkcan S; Gjorgjieva M; Correia de Sousa M; Foti M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232334
[TBL] [Abstract][Full Text] [Related]
6. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
Charrez B; Qiao L; Hebbard L
World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
9. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
10. The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease.
Pennisi G; Celsa C; Giammanco A; Spatola F; Petta S
Curr Pharm Des; 2020; 26(32):3928-3938. PubMed ID: 32436818
[TBL] [Abstract][Full Text] [Related]
11. Understanding the Role of Perilipin 5 in Non-Alcoholic Fatty Liver Disease and Its Role in Hepatocellular Carcinoma: A Review of Novel Insights.
Mass Sanchez PB; Krizanac M; Weiskirchen R; Asimakopoulos A
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067931
[TBL] [Abstract][Full Text] [Related]
12. Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis.
Masarone M; Troisi J; Aglitti A; Torre P; Colucci A; Dallio M; Federico A; Balsano C; Persico M
Metabolomics; 2021 Jan; 17(2):12. PubMed ID: 33458794
[TBL] [Abstract][Full Text] [Related]
13. Animal Models of Non-alcoholic Fatty Liver Diseases and Its Associated Liver Cancer.
Lau JKC; Zhang X; Yu J
Adv Exp Med Biol; 2018; 1061():139-147. PubMed ID: 29956212
[TBL] [Abstract][Full Text] [Related]
14. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches.
Borrelli A; Bonelli P; Tuccillo FM; Goldfine ID; Evans JL; Buonaguro FM; Mancini A
Redox Biol; 2018 May; 15():467-479. PubMed ID: 29413959
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease is associated with heterogeneous pattern of fat infiltration in skeletal muscles.
Nachit M; Dioguardi Burgio M; Abyzov A; Garteiser P; Paradis V; Vilgrain V; Leclercq I; Van Beers BE
Eur Radiol; 2024 Mar; 34(3):1461-1470. PubMed ID: 37658893
[TBL] [Abstract][Full Text] [Related]
16. Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis.
Xu G; Wang YM; Ying MM; Chen SD; Li ZR; Ma HL; Zheng MH; Wu J; Ding C
Clin Mol Hepatol; 2021 Apr; 27(2):329-345. PubMed ID: 33465844
[TBL] [Abstract][Full Text] [Related]
17. Autophagy, NAFLD and NAFLD-Related HCC.
Wu WKK; Zhang L; Chan MTV
Adv Exp Med Biol; 2018; 1061():127-138. PubMed ID: 29956211
[TBL] [Abstract][Full Text] [Related]
18. The Role of RECK in Hepatobiliary Neoplasia Reveals Its Therapeutic Potential in NASH.
Dashek RJ; Diaz C; Chandrasekar B; Rector RS
Front Endocrinol (Lausanne); 2021; 12():770740. PubMed ID: 34745017
[TBL] [Abstract][Full Text] [Related]
19. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
Wang K; Wei Y; Xu R; Li Y; Mao C
Adv Exp Med Biol; 2022; 1372():157-168. PubMed ID: 35503180
[TBL] [Abstract][Full Text] [Related]
20. Recombinant FGF21 Attenuates Polychlorinated Biphenyl-Induced NAFLD/NASH by Modulating Hepatic Lipocalin-2 Expression.
Kim HY; Yoo YH
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
